# VeriSIM Life

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/verisim-life

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: http://www.verisimlife.com
- Total disclosed funding: $22M
- Latest round: Series A (Jan 6, 2022)
- Investors on record: 11

## About

VeriSIM Life is an innovative firm specializing in AI-driven solutions for drug discovery and development, leveraging advanced technologies to enhance clinical trial efficiency and accuracy.Founded in 2017, VeriSIM Life is based in San Francisco, US, and focuses on revolutionizing drug development through its BIOiSIM platform. Jo Varshney, the founder and CEO, has a history of leading innovative companies. The company has raised a total of USD 15.00 mn in funding through its Series A round led by Morpheus Ventures, with participation from notable investors including Colorcon Ventures and Intel Capital. The company has completed 5 funding deals, with its current valuation at USD 46.00 mn.VeriSIM Life specializes in AI-driven drug discovery and development, offering solutions that improve the efficiency and accuracy of transitioning drug candidates into clinical trials. The BIOiSIM platform features an inferential search space of 1 billion drug-like compounds and utilizes advanced generative AI and deep learning techniques. The platform includes the AtlasGEN Novel Drug Designer, which identifies new molecules and assesses their clinical safety and effectiveness via the proprietary Translational Index™ technology, serving clients across North America and Europe.VeriSIM Life generates revenue through subscription-based services and strategic partnerships within the pharmaceutical and biotechnology sectors. Clients gain access to the BIOiSIM platform and its services through these subscriptions, which enable the use of advanced AI in drug discovery and clinical trial simulations. The company also engages in risk-sharing collaborations that involve joint investment in promising drug candidates, with pricing tailored to the specific services utilized, including AtlasGEN technology and data analytics services.VeriSIM Life plans to expand its product offerings and enhance its services in the drug discovery space. With the recent funding from Noname Ventures, the company aims to accelerate the development of new features within its BIOiSIM platform and broaden its market reach into additional regions beyond North America and Europe. Specific geographic areas for expansion have not been detailed yet, but this growth is anticipated to occur within the next two years.

## Funding rounds

- Series A, Jan 6, 2022, $15M — Intel Capital, OCA Ventures, Serra Ventures, Susa Ventures, Morpheus Ventures, Debiopharm Innovation Fund, Colorcon Ventures
- Seed, Jul 31, 2019, $6.5M — Amplify Partners, TenOneTen Ventures, Stage Venture Partners, Village Global

## Investors

- Amplify Partners (https://capitalatlas.ai/funds/amplify-partners) — Seed
- TenOneTen Ventures (https://capitalatlas.ai/funds/tenoneten-ventures) — Seed
- Stage Venture Partners (https://capitalatlas.ai/funds/stage-venture-partners) — Seed
- Village Global (https://capitalatlas.ai/funds/village-global) — Seed
- Intel Capital (https://capitalatlas.ai/funds/intel-capital) — Series A
- OCA Ventures (https://capitalatlas.ai/funds/oca-ventures) — Series A
- Serra Ventures (https://capitalatlas.ai/funds/serra-ventures) — Series A
- Susa Ventures (https://capitalatlas.ai/funds/susa-ventures) — Series A
- Morpheus Ventures (https://capitalatlas.ai/funds/morpheus-ventures) — Series A
- Debiopharm Innovation Fund (https://capitalatlas.ai/funds/debiopharm-innovation-fund) — Series A
- Colorcon Ventures (https://capitalatlas.ai/funds/colorcon-ventures) — Series A